Black Diamond Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on creating and advancing precision oncology medicines for patients with significant unmet medical needs. Its strategy centers on developing “MasterKey” therapies-engineered small-molecule drugs designed to selectively target genetically defined tumors across multiple cancer types. These therapies aim to address key challenges in modern oncology, including drug resistance, toxicity caused by inhibiting normal (wild-type) proteins, and the difficulty of treating cancers that spread to or arise in the central nervous system (CNS). A major differentiator of the company’s approach is the intent to design compounds that can penetrate the brain, improving their potential utility in CNS tumors and metastases. Black Diamond operates as a single reportable segment dedicated to developing selective treatments for cancers driven by oncogenes activated through allosteric mutations. Its pipeline includes three main programs: BDTX-4933, BDTX-1535 (Silevertinib), and BDTX-4876. The lead candidate, BDTX-4933, is being developed as a brain-penetrant, highly potent, and selective inhibitor of oncogenic BRAF across Class I, II, and III alterations, as well as active RAF dimers that can arise due to upstream oncogenic changes such as RAS mutations. The drug is designed with the goal of avoiding paradoxical activation, a known issue with some RAF-targeting therapies. Silevertinib (BDTX-1535) is a small-molecule inhibitor intended to address a broad range of EGFR mutations, including both canonical and allosteric variants. It is being evaluated in glioblastoma and other solid tumors, including non-small cell lung cancer (NSCLC), particularly where the disease affects the brain and spine. BDTX-4876 is in preclinical development for solid tumors and targets oncogenic FGFR2/3 mutations, while maintaining selective activity against FGFR1/4. Underlying these programs is the company’s proprietary Mutation-Allostery-Pharmacology (MAP) platform, which analyzes population-scale genetic sequencing data to identify mutation families that drive cancer and supports the development of single therapies capable of targeting each family.

Black Diamond is focused on developing innovative therapies targeting broad families of oncogenic mutations through its MasterKey approach. The company has generated two clinical-stage MasterKey drug candidates: Silevertinib for patients with EGFR-mutant NSCLC or GBM, and BDTX-4933 for patients with RAF/RAS-mutant tumors. The company is also involved in research activities, drug discovery efforts, and the development of product candidates, with expenses incurred for preclinical studies, clinical trials, and regulatory compliance. The R&D unit of Black Diamond is responsible for conducting necessary preclinical studies and clinical trials, managing agreements with contract research organizations (CROs) and contract manufacturing organizations (CMOs), and ensuring compliance with regulatory requirements. The unit also handles employee-related expenses and facilities-related costs associated with research and development functions. In FY2025, it spent US$33.5 million on R&D, which decreased by 34.5% YoY. As of February 2026, the company had four US provisional patent applications, eight US patent applications, two issued US patents, nine Patent Cooperation Treaty (PCT) patent applications, 127 foreign patent applications, and 18 issued foreign patents.